tbuckley/cabot-search huggingface dataset:
Pre-treatment PSA velocity (PSAV) is not predictive of outcomes after radical prostatectomy (RP) in a referral cohort
Authors: A. Hung, L. P. Depaula, S. Mongoue-Tchokote, M. Garzotto
Journal: Journal of Clinical Oncology (2006)

4619 Background: PSA velocity has recently been reported as a significant predictor of prostate cancer-specific mortality in early-staged cancer patients selected from a large screening trial where the median PSA was 4.3ng/ml. In order to determine the broad applicability of these data to a more general population, we examined the effect of PSAV in a referral cohort. Methods: We analyzed over 643 prostate cancer cases diagnosed from 1995–2005. 196 patients underwent RP as definitive therapy. One patient received neoadjuvant hormonal therapy and was excluded. Our goal was to identify whether PSAV prior to RP was predictive of Relapse-Free Survival (RFS) and Overall Survival (OS). 156 patients had at least 2 pre-op PSA values available for the calculation of PSAV (median = 3 values/patient). PSAV was calculated by linear regression analysis using all pre-treatment PSA values available. Results: With a median f/u of 54 months, there were 14 deaths and 26 patients had biochemical relapse. At 5 years, OS was 93% and RFS was 91%. Surprisingly, no patients with biochemical relapse have died, and thus prostate cancer-specific mortality is 0%. In addition to the variables in the table below, seminal vesicle involvement (p = 0.015) and margin positivity (p=0.005) were also significantly associated with RFS confirming the expected prognostic factors in our cohort. On multivariate analysis, Gleason Grade was the only significant predictor of overall survival. For RFS, Gleason Grade, margin involvement, and pre-treatment PSAs were the only significant variables. Neither PSAV nor PSA Doubling Time were significantly associated with RFS or OS by univariate or multivariate analysis. Conclusions: Pre-treatment PSAV is not significantly associated with prostate cancer outcomes in a heterogenous population referred for an elevated PSA. Gleason Grade is still the most significant predictor of overall survival. [Table: see text] No significant financial relationships to disclose.
Autoantibodies against the platelet glycoproteins (GP) IIb/IIIa, Ia/IIa, and IV and partial deficiency in GPIV in a patient with a bleeding disorder and a defective platelet collagen interaction
Authors: JH Beer, M Rabaglio, P Berchtold, A von Felten, KJ Clemetson, DA Tsakiris, B Kehrel, S Brandenberger
Journal: Blood (1993)
A structured spiritual service for cancer patients and families: Analysis of attendee responses
Authors: N. J. Dann, D. J. Higby, W. C. Mertens
Journal: Journal of Clinical Oncology (2004)

8133 Background: Compared to reported importance of religion and spirituality to Americans, investigation and reporting of attendee satisfaction and emotional response to spiritual programs for cancer patients and families is lacking. Methods: The content of a program, A Sacred Gathering for Those Touched by Cancer, was developed with clergy of different denominations and presented in two Catholic and two Protestant churches. The service included key themes (surrendering fear, peace, hope, community support, and God's love) reinforced by Scripture, music, ritual and prayer. Patient and staff participation was encouraged. Questionnaires evaluating attendee characteristics, emotional reaction to the service and satisfaction with service components were distributed. Results: Attendees returned 450 questionnaires. Most were women (80%) and Catholic (71%); half were over age 50. Most found the service very (83%) or somewhat (14%) helpful. In a stepwise regression model, perception that the service was helpful was associated with perception that the service made the respondent feel hopeful (p<.0001), that the respondent attached importance to inspirational messages (p=.058), and that the respondent was a current patient (p=.018). Stepwise regression also indicated those patients who reported an angry response tended to be current patients (p=0.0044). Men tended to feel less loved by God (p=0.012) and people (p=0.034), and less hopeful (p=0.057) than women. Men liked music less (p=0.048), the Scripture and prayers concerning community less (p=0.040), and found prayer (p=0.0035) and the litany of hope (p=0.043) less important than women. However, men felt that the gatherings were as helpful as women did. Evaluation of attendee characteristics reveals that past patients felt less sadness than others (p=.0084) while current patients felt more anger (p=.0010). Conclusions: While almost all attendees found the service somewhat or very helpful, distinct preferences and reactions to the service were noted for gender, patient status and religious affiliation. This evaluation will help tailor future events to better meet the spiritual needs of cancer patients. No significant financial relationships to disclose.
Gene expression profiling predicts survival in clear cell renal cell carcinoma
Authors: M.-H. Tan, B. T. Teh
Journal: Journal of Clinical Oncology (2005)

4534 Background: Predicting individual survival in clear cell renal cell carcinoma (ccRCC) is challenging as tumor progression is often unpredictable. As ccRCC has a high prevalence of von Hippel-Lindau (VHL) mutations, substantial research efforts have focused on angiogenesis and hypoxia-response pathways in ccRCC progression. Methods: We performed an international multicenter gene expression profiling study. 105 oligonucleotide expression profiles (54,675 probe sets) and 42 spotted cDNA expression profiles (21,103 clones) were generated from 110 primary tumors and 13 distant metastatic tumors, with up to 15 years follow-up. The prognostic gene predictors were derived by supervised principal components analysis with an external validation study design. The endpoint was disease-specific mortality. Immunohistochemical studies were performed on 45 tissue samples for further predictor validation. Regional expression biases were assessed by comparative genomic microarray analysis. 96 of 110 primary tumors were sequenced for VHL gene mutations. Results: We obtained both continuous and discrete gene predictors demonstrating excellent externally-validated survival predictions (Table 1). On multivariate analysis, these predictors were independent of standard clinicopathologic parameters, including metastatic status and the UCLA integrated staging system. These predictors translated well across array platforms, and were validated on immunohistochemistry. We identified novel regional expression biases and pathways determining survival. While VHL mutation status did not correlate with prognosis, we identified a genetically distinct tumor cluster characterized by a high rate of VHL mutation. Conclusions: We have established gene predictors that predict individual survival independently of standard clinico-pathological parameters. The results of our study have implications for targeted therapy development and therapeutic trials in ccRCC. No significant financial relationships to disclose.
Analysis of Tumor Lysis Syndrome Treated in Our Hospital
Authors: Yusuke Okamoto, Taku Tsukamoto, Hiroyuki Sugiura, Hiroyuki Matsui, Tomoaki Ueda, Kazuya Okada, Tomoyasu Jo, Tatsuhito Onishi, Takeshi Maeda, Yasunori Ueda
Journal: Annals of Oncology (2014)
Phase I study of CHP-HER2 polyvalent cancer vaccine, HER2 protein combined with a novel nanoparticle antigen delivery system of cholesteryl hydrophobized polysaccharides
Authors: S. Kageyama, S. Kitano, Y. Nagata, A. Hiasa, Y. Miyahara, H. Imai, R. Murphy, A. M. Scott, E. W. Hoffman, L. J. Old, H. Shiku
Journal: Journal of Clinical Oncology (2005)

2523 Background: Cholesteryl hydrophobized polysacharide-HER2 protein complex (CHP-HER2) is a cancer vaccine with a novel nanoparticle antigen delivery system, which is a complex of hydrophobized polysaccharides, pullulan (CHP) and truncated HER2 protein. Antigen-presenting cells, after incorporating CHP-HER2, can process the HER2 protein and present both MHC class I and class II-binding peptides, suggesting immunization with CHP-HER2 elicits both CD8+ and CD4+ T cell responses against HER2 antigens. Methods: Phase I trial of CHP-HER2 vaccine (LUD01–016) were conducted for HLA-A2402-positive patients with HER2-expressing refractory cancers. CHP-HER2 vaccine was subcutaneously injected every two weeks for three times at the dose of 300 micrograms of HER2 protein. The endpoints were its toxicity and specific immune reactions to HER2 antigens. Results: Nine patients were enrolled, including four patients with breast cancer, two with non-small cell lung cancer, and one each with pancreatic, urinary pelvic, and nasal cavity cancer. Adverse events were transient skin reactions at the injection sites (grade I) in all nine patients. No other adverse events were seen. During the trial, no tumor responses were observed, where eight cases with stable disease and one with progressive disease were seen. The median period of time-to-progression was 5 months. In all patients with more than three vaccinations, IgG antibodies against HER2 protein were detected. Western blot analysis showed that the antibodies also specifically reacted with the full-length HER2 molecules. For T cell immune responses, we prepared autologous PHA-stimulated CD4+ blasts (T-APCs) transduced with mRNA encoding HER2. The T-APC cells were used both for in vitro T cell stimulation and for target cells in ELISPOT assays. Specific CD8+ and CD4+ T cells became detectable after eight vaccinations, which subsequently increased in frequency with additional vaccinations. HER2-specific T-cell immune responses have been detected in three out of six vaccinated patients to date. Conclusions: CHP-HER2 is safe, and it induces both humoral and cellular immune responses to HER2 antigens. No significant financial relationships to disclose.
Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design
Authors: Chinedu O. Mmeje, Charles C. Guo, Jay B. Shah, Neema Navai, H. Barton Grossman, Colin P. Dinney, Ashish M. Kamat
Journal: European Urology (2016)
Immunosuppressive Effects of Friend and Rauscher Leukemia Disease Viruses on Cellular and Humoral Antibody Formation&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Walter S. Ceglowski, Herman Friedman
Journal: JNCI Journal of the National Cancer Institute (1968)

Infection of mice with either Rauscher or Friend viruses, which induce leukemia-like disease, markedly interfered with antibody production on the cellular level, after immunization with sheep red blood cells (S-RBC), as detected by a localized hemolytic plaque assay for 19S and 7S antibody-forming cells. Cellular immunodepression was noted quite early and throughout the period after immunization when control animals were responding well with antibody formation. Mice simultaneously infected with virus and given injections of S-RBC had a slightly suppressed, immune, antibody-plaque response at the time of peak antibody formation 4 days later. Lengthening the interval between virus infection and S-RBC immunization resulted in greater immunosuppression. The number of antibody-forming cells after immunization was markedly depressed in virus-infected mice when calculated either as a ratio for the whole spleen or as the number of antibody-forming cells per million nucleated spleen lymphocytes. There was no compensatory increase of antibody-forming cells in lymph nodes and the thymus of virusinfected mice, as compared to noninfected controls. The appearance of antibody in the circulation decreased, as assayed by hemagglutination and hemolysis titrations of serum from virus-infected mice, compared to normal controls. Serum antibody suppression was not as marked as that observed on the cellular level. Virus-infected mice also had a suppressed secondary response when S-RBC were administered 10–15 days after the primary immunization. Appearance of both 7S and 19S antibody-forming cells was suppressed in the secondary-stimulated mice. Although immunodepression was detectable in all mice infected with virus before primary immunization, the most marked suppression was observed in animals with marked splenomegaly relatively late in the disease process. Total spleen weight and number of nucleated spleen cells increased after infection and were correlated with reduced numbers of antibody-forming cells. The results are discussed in relation to other studies indicating depressed immune responses to a number of antigens after infection of mice with a variety of tumor viruses or after treatment with carcinogens.
48 weeks of adefovir dipivoxil (ADV) results in improvement in fibrosis and decreased progression of fibrosis in a double-blind, randomized, placebo-controlled study for the treatment of patients with HBeAg plus chronic hepatitis B.
Authors: Zack Goodman, P Marcellin, Ting-Tsung Chang, Seng-Gee Lim, Myron Tong, W Sievert, M Shiffman, L Jeffers, M Wulfsohn, R Fallis, J Fry, C Brosgart
Journal: Hepatology (2002)
Bevacizumab (B), cisplatin, and vinorelbine in chemotherapy-naive patients (p) with nonsquamous non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study
Authors: L. Leon, S. Vázquez, J. M. Gracia, M. Lázaro, J. L. Fírvida, J. Casal, M. Amenedo, L. Santomé, R. Gallego, U. Anido
Journal: Journal of Clinical Oncology (2009)

e19089 Background: Bevacizumab, an anti-VEGF monoclonal antibody, improves response rates and prolongs survival in p with non squamous NSCLC when combined with carboplatin-paclitaxel or cisplatin-gemcitabine. This single-arm, open-labeled phase II trial aims to evaluate the efficacy and safety profile of B in combination with another widely used chemotherapy doublet for NSCLC: cisplatin and vinorelbine. Methods: Chemotherapy-naïve p diagnosed with stage IIIB or IV non squamous NSCLC received cisplatin (80 mg/m2), vinorelbine (25 mg/m2 IV days 1 and 8) and B (15 mg/kg IV) on day 1 every 3 weeks for up to 6 cycles followed by B 15 mg/kg alone every 3 weeks until disease progression. Main eligibility criteria were: PS 0–1, no brain metastases, no history of hemoptysis, stable cardiac condition and no full dose anticoagulation. Primary endpoint was progression-free survival and secondary endpoints were RR, duration of response, OS, 1-year survival and safety profile of the combination. Results: 38 p have been enrolled in the study and data of 27 p have been included in this analysis. P characteristics were: male 66.7%; median age 57 years (range 41–74); ECOG PS 0/1 (%) 33.3/66.7; adenocarcinoma/other (%) 74.1/25.9; stage IIIB/IV (%) 25.9/74.1. Median number of cycles for B/cisplatin/vinorelbine was 4.0 (range 1–6) and median number of cycles for B maintenance was 2 (range 1–4). 17 p were evaluable for response according to RECIST criteria: PR 29.4% and SD 41.2%. With a median follow-up of 3.9 months (range 0.7–11.1), median PFS was 4.6 months (95% CI: 2.6–6.6) and median OS has not been reached yet. Hematological toxicities were: 1 p gr. 3 anemia; 2 p gr. 3 and 2 p gr. 4 leucopenia; 10 p gr. 3, 1 p gr. 4 neutropenia and 3 p febrile neutropenia. Most common grade 3/4 non hematological toxicities were: vomiting (1p gr. 4), high blood pressure, asthenia and hyperglycemia. 1 p experienced gr. 4 abdominal pain, 1 p. gr. 4 constipation, 1 p. gr. 4 nausea and 1 p gr. 4 respiratory infection. No grade 3/4 hemoptysis were reported. Conclusions: This interim analysis shows that B in combination with cisplatin and vinorelbine is safe and well tolerated and has a promising activity in chemo-naïve p with non squamous NSCLC. Survival data will be updated. [Table: see text]
Intubation trauma and the head and neck surgeon: issues with a shared airway
Authors: Jenny Montgomery, Louise Melia, Neil O’Donnell, Kenneth MacKenzie
Journal: Journal of the Royal Society of Medicine (2015)

Injury to the larynx following intubation occurs in one-third of all patients. The national audit of the Royal College of Anaesthetists found that the larynx is the site most frequently injured (80%). 1 This may present difficult with adequate laryngeal assessment in patients undergoing microlaryngeal surgery. Trauma to intraluminal airway contents can occur. Unlike many anaesthetic challenges, this situation can be anticipated. Virtually all patients undergoing head and neck surgery have had direct flexibile laryngoscopy. As a result, many difficult situations can be pre-empted but despite this laryngeal trauma does occur. With benign laryngeal lesions, surgical outcomes are voice improvement and histological diagnosis without deterioration in voice. Iatrogenic injury to professional voice users may in time present a medicolegal challenge. 3 Patient-reported outcome measures are increasingly used following microlaryngeal surgery and are the proposed subject matter for personal audit to provide evidence for revalidation in the United Kingdom. This may have implications for the surgeon.
Abstract 11661: A Family History of Premature Coronary Artery Disease is Associated With Location and Severity of Angiographically Defined Coronary Artery Stenosis
Authors: Muhammad Hammadah, Riyaz S Patel, Danny J Eapen, Ayman Samman Tahhan, Nima Ghasemzadeh, Hatem Al Kassem, Mohamed Khayata, Pankaj Manocha, Mosaab Awad, Ibrahim Kassas, Ayman Alkhoder, Emir Veledar, Arshed A Quyyumi
Journal: Circulation (2014)

Introduction: A family history (FH) of premature coronary artery disease (CAD) is an important prognostic risk factor. Emerging evidence suggests that CAD location as well as severity may be heritable. We sought to investigate the association between a FH of premature CAD with the location and severity of angiographically phenotyped CAD. Methods: 2854 patients undergoing coronary angiography were enrolled from the Emory Cardiovascular Biobank. A FH of CAD was defined as having any male or female relative with history of CAD at age ≤55 or ≤65 year old respectively. Coronary angiograms were phenotyped using a 17 segment AHA model. Proximal disease was defined as having ≥70% lesion in the left main or proximal portion of any of the three major epicardial arteries, while CAD severity was assessed by counting the number of vessels with ≥70% stenosis. Results: Among this population (mean age 63±12, male 67%, diabetes 33%), 21% reported a positive FH of premature CAD. After adjustment for age, gender, and traditional cardiovascular risk factors, those with a positive FH were more likely to have significant CAD than those without a positive FH (OR 1.3 (1.1-1.7)). They were 40% more likely to have single vessel (OR 1.4(1.1-1.7)) and up to 80% more likely to have multi-vessel disease (OR 1.8 (1.4-2.4)). In addition, they were also much more likely to have left main (OR 1.9 (1.3-2.8)) and proximal vessel involvement (OR 1.5 (1.2 - 1.9)), but not distal vessel stenosis (OR 1.1 (0.9-1.4)). Conclusions: A FH of CAD is associated with a greater likelihood of multi-vessel and proximal anatomical disease. Whether site specific disease is genetically mediated remains to be explored.
DNA repair targeted therapy: The past or future of cancer treatment?
Authors: Navnath S. Gavande, Pamela S. VanderVere-Carozza, Hilary D. Hinshaw, Shadia I. Jalal, Catherine R. Sears, Katherine S. Pawelczak, John J. Turchi
Journal: Pharmacology & Therapeutics (2016)

The repair of DNA damage is a complex process that relies on particular pathways to remedy specific types of damage to DNA. The range of insults to DNA includes small, modest changes in structure including mismatched bases and simple methylation events to oxidized bases, intra- and interstrand DNA crosslinks, DNA double strand breaks and protein-DNA adducts. Pathways required for the repair of these lesions include mismatch repair, base excision repair, nucleotide excision repair, and the homology directed repair/Fanconi anemia pathway. Each of these pathways contributes to genetic stability, and mutations in genes encoding proteins involved in these pathways have been demonstrated to promote genetic instability and cancer. In fact, it has been suggested that all cancers display defects in DNA repair. It has also been demonstrated that the ability of cancer cells to repair therapeutically induced DNA damage impacts therapeutic efficacy. This has led to targeting DNA repair pathways and proteins to develop anti-cancer agents that will increase sensitivity to traditional chemotherapeutics. While initial studies languished and were plagued by a lack of specificity and a defined mechanism of action, more recent approaches to exploit synthetic lethal interaction and develop high affinity chemical inhibitors have proven considerably more effective. In this review we will highlight recent advances and discuss previous failures in targeting DNA repair to pave the way for future DNA repair targeted agents and their use in cancer therapy.
Ongoing outbreak of an acute muscular Sarcocystis-like illness among travellers returning from Tioman Island, Malaysia, 2011-2012
Authors: D H Esposito, D O Freedman, A Neumayr, P Parola
Journal: Eurosurveillance (2012)

As of 4 November, 2012, 100 patients with an acute muscular Sarcocystis-like illness associated with travel to Tioman Island, Malaysia, have been identified. Thirty-five travelled there mostly during July and August 2011 and 65 mostly during July and August 2012, suggesting an ongoing outbreak. Epidemiological investigations are ongoing. Public health agencies and practicing clinicians should be aware of this rarely-reported disease in humans and consider it as differential diagnosis in travellers returning from Tioman Island.
Skin metastases from unknown origin: Protein expression profiling helps in assessing the primary origin
Authors: S. Azoulay, F. Lepelletier, G. Le Naour, A. Gloaguen, S. Laye, F. Capron, C. Adem
Journal: Journal of Clinical Oncology (2004)

9676 Background: Determining the primary origin of a skin metastasis is a challenging issue for surgical pathologists. Moreover, the patient personal history is often unknown to the pathologist. Many antibodies, directed against selective biomarkers including cytokeratins, are being available. However, they were rarely assessed collectively in this setting using tissue array. Methods: Forty four cases of skin metastases were retrieved from our Department's files. Patient's history was collected whenever available. Slides were reviewed independently by 2 pathologists, blinded to patients' clinical data. A priori primary site was evaluated based on the morphological characteristics of the tumor. Paraffin blocks were collected, and 1mm punch was performed using a home made manual tissue arrayer. Multiple serially cut sections from the 2 tissue array blocks were done and evaluated by 13 antibodies (CK5/6, CK7, CK19, CK20, TTF-1, ACE, PS100, Tag-72, BerEP4, E-cadherin, ER, PR, and CD10) using an automated immunohistochemistry technique. Results: There were 26 women and 18 men (age range, 32y- 96y). In only seventeen cases (38%) was a correct primary origin assigned based on the morphological data alone. BerEP4, CK20 and CK7 stained respectively 100%, 60% and 20% of colo-rectal metastases, 27%, 0% and 66% of mammary metastases and 64%, 14% and 58% of others tumors. ER and/or PR highlighted 75% of mammary metastases and none of the remaining metastases.CK5/6, CD10, TTF-1, and PS100 did not stain any of the colo-rectal and mammary metastases. CK19, ACE, E-cadherin, Tag72 were not specific of any primary site in this series. Conclusions: We have shown the utility of a specific pattern of protein expression in assessing the primary origin of skin metastases. In this specific series, CK20 and ER/PR are the most helpful antibodies in assessing the primary origin of skin metastases. This pattern depends on the local hospital environment and has to be adapted in agreement. No significant financial relationships to disclose.
GW26-e2438 Efficacy and safety of low-dose β-blocker for the treatment of vasovagal syncope
Authors: Jie-ming Zhu, Rui-min Dong, Zhen-da Zheng, Xu-jing Xie, Yan-ting Luo, Yu-eng Liang, Su-hua Li, Lin Chen, Jin-lai Liu
Journal: Journal of the American College of Cardiology (2015)